| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
1 Division of Hematology, Department of Medicine, Brigham and Women’s Hospital; 2 Dana-Farber Cancer Institute; and 3 Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts; 4 Department of Human Genetics, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium; 5 Novartis Pharma, Basel, Switzerland
Mutations in the receptor tyrosine kinase FLT3 occur frequently in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Small molecules that selectively inhibit FLT3 kinase activity induce apoptosis in blasts from AML patients with FLT3 mutations and prolong survival in animal models of FLT3-induced myeloproliferative disease. A spectrum of structurally different small molecules with activity against FLT3 have been described, and their efficacy for treatment of AML and ALL is now being investigated in clinical trials. Here, we describe the results of an in vitro screen designed to identify mutations in the ATP-binding pocket of FLT3 that confer resistance to tyrosine kinase inhibitors. Mutations at four different positions (Ala-627, Asn-676, Phe-691, and Gly-697) were identified that confer varying degrees of resistance to PKC412, SU5614, or K-252a. FLT3 proteins mutated at Ala-627, Asn-676, or Phe-691 remained sensitive to higher concentrations of the inhibitors, but the G697R mutation conferred high-level resistance to each of these inhibitors as well as to six additional experimental inhibitors. These data provide insights into potential mechanisms of acquired resistance of FLT3 to small molecule inhibitors and indicate that the G697R mutation may be a clinically problematic resistance mutation that warrants proactive screening for additional inhibitors.
This article has been cited by other articles:
|
|
 |
|
  Y.-J. Chiu, E. McBeath, and K. Fujiwara Mechanotransduction in an extracted cell model: Fyn drives stretch- and flow-elicited PECAM-1 phosphorylation J. Cell Biol., August 25, 2008; 182(4): 753 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Trowe, S. Boukouvala, K. Calkins, R. E. Cutler Jr., R. Fong, R. Funke, S. B. Gendreau, Y. D. Kim, N. Miller, J. R. Woolfrey, et al. EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation Clin. Cancer Res., April 15, 2008; 14(8): 2465 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Weisberg, L. Banerji, R. D. Wright, R. Barrett, A. Ray, D. Moreno, L. Catley, J. Jiang, E. Hall-Meyers, M. Sauveur-Michel, et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells Blood, April 1, 2008; 111(7): 3723 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. Barry, J. J. Clark, J. Cools, J. Roesel, and D. G. Gilliland Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin Blood, December 15, 2007; 110(13): 4476 - 4479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Weisberg, A. L. Kung, R. D. Wright, D. Moreno, L. Catley, A. Ray, L. Zawel, M. Tran, J. Cools, G. Gilliland, et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells Mol. Cancer Ther., July 1, 2007; 6(7): 1951 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ray, S. W. Cowan-Jacob, P. W. Manley, J. Mestan, and J. D. Griffin Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study Blood, June 1, 2007; 109(11): 5011 - 5015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Piloto, M. Wright, P. Brown, K.-T. Kim, M. Levis, and D. Small Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways Blood, February 15, 2007; 109(4): 1643 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lierman, I. Lahortiga, H. Van Miegroet, N. Mentens, P. Marynen, and J. Cools The ability of sorafenib to inhibit oncogenic PDGFR{beta} and FLT3 mutants and overcome resistance to other small molecule inhibitors Haematologica, January 1, 2007; 92(1): 27 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Bradeen, C. A. Eide, T. O'Hare, K. J. Johnson, S. G. Willis, F. Y. Lee, B. J. Druker, and M. W. Deininger Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood, October 1, 2006; 108(7): 2332 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Teicher Protein kinase C as a therapeutic target. Clin. Cancer Res., September 15, 2006; 12(18): 5336 - 5345. [Full Text] [PDF]
|
|
|
|
|
|
M. Koptyra, R. Falinski, M. O. Nowicki, T. Stoklosa, I. Majsterek, M. Nieborowska-Skorska, J. Blasiak, and T. Skorski BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance Blood, July 1, 2006; 108(1): 319 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Parcells, A. K. Ikeda, T. Simms-Waldrip, T. B. Moore, and K. M. Sakamoto FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia Stem Cells, May 1, 2006; 24(5): 1174 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Adam, V. Pogacic, M. Bendit, R. Chappuis, M. C. Nawijn, J. Duyster, C. J. Fox, C. B. Thompson, J. Cools, and J. Schwaller Targeting PIM Kinases Impairs Survival of Hematopoietic Cells Transformed by Kinase Inhibitor-Sensitive and Kinase Inhibitor-Resistant Forms of Fms-Like Tyrosine Kinase 3 and BCR/ABL. Cancer Res., April 1, 2006; 66(7): 3828 - 3835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Heidel, F. K. Solem, F. Breitenbuecher, D. B. Lipka, S. Kasper, M. H. Thiede, C. Brandts, H. Serve, J. Roesel, F. Giles, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain Blood, January 1, 2006; 107(1): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Stover, J. Chen, B. H. Lee, J. Cools, E. McDowell, J. Adelsperger, D. Cullen, A. Coburn, S. A. Moore, R. Okabe, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR{beta} and FIP1L1-PDGFR{alpha} in vitro and in vivo Blood, November 1, 2005; 106(9): 3206 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kobayashi, H. Ji, Y. Yuza, M. Meyerson, K.-K. Wong, D. G. Tenen, and B. Halmos An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor Cancer Res., August 15, 2005; 65(16): 7096 - 7101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Lopes de Menezes, J. Peng, E. N. Garrett, S. G. Louie, S. H. Lee, M. Wiesmann, Y. Tang, L. Shephard, C. Goldbeck, Y. Oei, et al. CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia Clin. Cancer Res., July 15, 2005; 11(14): 5281 - 5291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chen and W. Plunkett Sequential Blockade of Oncogenic Kinases Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 344 - 348. [Full Text] [PDF]
|
|
|
|
|
|
W. L. Carroll On target for advances in the treatment of childhood acute lymphoblastic leukemia Blood, January 15, 2005; 105(2): 438 - 439. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
